Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”)
today announced that members of the management team will present a
corporate overview at the 2019 Bloom Burton & Co. Healthcare Investor
Conference on Tuesday, April 30, 2019 at 8:30am PT (11:30am ET) in
Toronto, Ontario.
The presentation will be webcast live and can be accessed via the
investor section of the Aurinia website, www.auriniapharma.com.
A replay of the presentation will also be archived on the Company
website following the event.
About Aurinia
Aurinia Pharmaceuticals Inc. is a late clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations impacted by serious
diseases with a high unmet medical need. The company is currently
developing voclosporin, an investigational drug, for the potential
treatment of lupus nephritis (LN), focal segmental glomerulosclerosis
(FSGS), and dry eye syndrome (DES). The company is headquartered in
Victoria, British Columbia and focuses its development efforts globally.
For further information, see our website at www.auriniapharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190424005984/en/
Copyright Business Wire 2019